October 28 next meeting of the Transparency Council.
AOTMiT: Transparency Council on preventive mastectomy, cystic fibrosis and newborn screening, among others
Published Oct. 28, 2024 07:54
Źródło: AOTMiT
The agenda includes:
1 Prepare a position paper on the legitimacy of expanding the eligibility criteria for the procedure Prophylactic mastectomy under the guaranteed benefit.
2 Prepare a position paper on the legitimacy of reimbursement of the medicinal product Lonsurf (Trifluridinum + Tipiracilum) under PL .4. "Treatment of patients with colorectal cancer (ICD-10: C18 - C20)".
3 Prepare a position paper on the appropriateness of reimbursement of the medicinal product Trodelva (sacituzumabum govitecanum) under the drug program B.9.FM. "Treatment of patients with breast cancer (ICD-10: C50)".
4 Prepare an opinion on the draft health policy program of the local government unit "Program of preventive vaccination against meningococcus type B children of the Municipality of Tarnowo Podgórne".
5 Prepare a position paper on the legitimacy of reimbursement of the medicinal product Kalydeco (ivacaftorum) within the framework of the drug program B.112. "Treatment of patients with cystic fibrosis (ICD-10: E84)".
6. Preparation of a position on the legitimacy of reimbursement of the medicinal product Kaftrio (ivacaftorum + tezacaftorum + elexacaftorum) within the framework of the drug program B.112. "Treatment of patients with cystic fibrosis (ICD-10: E84)".
7 Prepare a position paper on the appropriateness of reimbursement of the medicinal product Nucala (mepolizumabum) under the drug program "Treatment of patients with active form of eosinophilic granulomatosis with vasculitis (EGPA) (ICD-10: M30.1)".
8 Prepare an opinion on the draft health policy program of the Ministry of Health "Program of newborn screening in the Republic of Poland for 2019-2026".
9. preparation of an opinion on continuation of reimbursement in off-label indications for the active substance nivolumab within the framework of drug program B.77 "Treatment of refractory and relapsed form of classical Hodgkin's lymphoma with nivolumab (ICD-10 C81)" for the indication: treatment of children aged 12-18 years with relapsed or refractory classical Hodgkin's lymphoma after autologous bone marrow stem cell transplantation and treatment with brentuximab with vedotin.
Source: AOTMiT
